Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Endocrine 1CNS 1

Conditions

Adrenocortical Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × gossypol acetic acid × Endocrine × Clear all
NCT00848016 2014-05-07

Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
29 enrolled 6 charts
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡